Sana Biotechnology, Inc.
SANA Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$2.47
KIRA · Stoqly’s AI analyst, in plain words
- Sana Biotechnology, Inc. lost $244M in fiscal 2025.
- Free cash flow was −$145M in fiscal 2025, — of revenue.
Market cap
$730M
P/E
—
Revenue
—
Net income
−$244M
Free cash flow
−$145M
Operating margin
—
Sana Biotechnology, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$244M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Sana Biotechnology, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 3, 2026
- Legal name
- Sana Biotechnology, Inc.
- CIK
- 0001770121
Sana Biotechnology, Inc. · SANA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$356M | −$269M | −$283M | −$267M | −$244M |
| Diluted EPS | −$2.14 | −$1.43 | −$1.46 | −$1.16 | −$0.96 |
| Cash | |||||
| Cash from operations | −$251M | −$290M | −$254M | −$223M | −$144M |
| Capital expenditure | $29.9M | $20.9M | $20.0M | $33.4M | $0.9M |
| Free cash flow | −$281M | −$311M | −$274M | −$257M | −$145M |
| Share count change | 1,178.9% | 13.2% | 3.3% | 18.7% | 9.7% |
| Debt and strength | |||||
| Cash and short-term investments | $551M | $424M | $205M | $152M | $138M |
| Shareholders' equity | $729M | $499M | $288M | $251M | $161M |
| Current ratio | 5.6x | 4.0x | 3.3x | 3.5x | 1.9x |
| Returns and quality | |||||
| Return on equity | −231.6% | −43.9% | −72.0% | −99.2% | −118.7% |
| Return on tangible equity | −67.3% | −90.0% | −323.0% | −526.3% | — |
| Altman Z'' | 0.2 | −2.1 | −8.4 | −11.5 | −16.7 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Sana Biotechnology, Inc. · SANA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.47 a share, the company is worth $730M.
Source: SEC EDGAR XBRL filings (CIK 0001770121). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.